Cardiovascular impact of switching to asciminib in chronic-phase chronic myeloid leukemia
Clicks: 1
ID: 323336
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #222 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Among adenosine triphosphate-competitive tyrosine kinase inhibitors (ATP-TKIs) approved for chronic-phase chronic myeloid leukemia (CP-CML), nilotinib and ponatinib are associated with a high incidence of vascular adverse events, and cardiovascular monitoring is recommended in current cardio-oncology guidelines. In contrast, monitoring strategies for asciminib, a recently approved specifically targets the myristoyl pocket (STAMP) inhibitor, have not been addressed, and its real-world vascular impact remains unclear. Purpose To compare surrogate markers of atherosclerosis before and after switching from ATP-TKIs to asciminib in patients with CP-CML. Method This single-centre retrospective observational study included patients with CP-CML followed at a dedicated cardio-oncology clinic. Patients switched from ATP-TKIs to asciminib were identified. Arterial stiffness parameters, including cardio-ankle vascular index (CAVI) and ankle-brachial index (ABI), were assessed before and after the switch. Cardiovascular events during follow-up were recorded. Results Among 102 patients in the cardio-oncology database, 45 were switched to asciminib. Thirty-two patients had complete arterial stiffness data before and after switching. Mean age at switching was 59.4 ± 12.8 years, and 65% were male. Approximately half had hypertension. No cardiovascular events requiring therapeutic intervention occurred during follow-up. ABI showed no significant change. In contrast, CAVI, a marker of arterial stiffness, showed a significant increase after asciminib initiation. Before switching, 21 patients had normal values (<8.0), 5 were borderline (8.0–8.9), and 6 were abnormal (≥9.0). Only one patient worsened from the normal to abnormal range. Conclusion Asciminib was not associated with clinically overt cardiovascular events in this cohort; however, a significant increase in arterial stiffness as assessed by CAVI was observed after treatment initiation. Given the age dependency of CAVI, causality cannot be confirmed. Larger studies are warranted to determine whether early increases in arterial stiffness are associated with future cardiovascular events and to clarify the need for vascular monitoring in these patients.
| Reference Key |
openalex_W7172268211
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | S Miyazaki, T Takaku, E Sato, N Watanabe, M Ando, T Minamino |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.117
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.